| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q2 | Jun 30, 2025 | ITUS Capital | - | - | AUROBINDO.NS, BAJAJ-AUTO.NS, CUB.NS, DRREDDY.NS, EICHERMOT.NS, GILLETTE.NS, HDFCAMC.NS, HDFCBANK.NS, HINDUSTANCOPPER.NS, HINDZINC.NS, ICICIBANK.NS, IGI.NS, INTERGLOBE.NS, ITC.NS, MARICO.NS, PBFINTECH.NS, PIRAMALP.NS, TITAN.NS, TVSMOTOR.NS, VEDL.NS | Banking, earnings, India, infrastructure, Pharmaceuticals, tariffs, Valuations | US tariff policies are creating global trade volatility and uncertainty. The manager discusses how tariffs protect domestic industries at the expense of consumers and global welfare, while potentially increasing inflation and devaluing currency. This uncertain environment requires global allocators to rethink their marginal dollar allocation. | View | |
| 2025 Q1 | Mar 31, 2025 | ITUS Capital | - | - | ABB.NS, AUROPHARMA.NS, BAJAJ-AUTO.NS, DRREDDY.NS, EICHERMOT.NS, GILLETTE.NS, HAVELLS.NS, HDFCAMC.NS, HDFCBANK.NS, HINDCOPPER.NS, ICICIBANK.NS, ICICIGI.NS, ITC.NS, MARICO.NS, PBFINTECH.NS, PIRAMALP.NS, TITAN.NS, TVSMOTOR.NS, ULTRACEMCO.NS, VEDL.NS | banks, consumer, Government Spending, India, large cap, Pharmaceuticals, tariffs, valuation | Portfolio is overweight banks with focus on market leaders like ICICI Bank and HDFC Bank. Manager expects bottoms-up outlook on lending growth and views banks as offering better risk-reward at current valuations. | View | |
| 2024 Q4 | Dec 31, 2024 | ITUS Capital | - | - | AMBUJACEM.NS, AUROPHARMA.NS, BAJAJ-AUTO.NS, DRREDDY.NS, EICHERMOT.NS, GAIL.NS, HAVELLS.NS, HDFCAMC.NS, HDFCBANK.NS, ICICIBANK.NS, IEX.NS, ITC.NS, KEI.NS, LT.NS, MARICO.NS, PBFINTECH.NS, PIRAMALP.NS, POWERGRID.NS, RELIANCE.NS, TVSMOTOR.NS | Capex, Copper, Domestic Flows, healthcare, India, infrastructure, technology, Two Wheelers | Healthcare continues to be the largest exposure across portfolios with strong growth outlook benefiting from low-cost manufacturing and lower price erosion in US pharma. The manager expects CY25 to be a strong growth sector for pharma which is reflected across portfolio positioning. | ICICIGI.NS |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| No pitches found. | |||||||||
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||